Comparative Pharmacology
Head-to-head clinical analysis: FLONASE versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLONASE versus SYNACORT.
FLONASE vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as cytokines, leukotrienes, and prostaglandins, thereby reducing nasal inflammation.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
2 sprays (50 mcg/spray) per nostril once daily; may increase to 2 sprays per nostril twice daily if needed. Intranasal route.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2-4 hours). This short half-life supports twice-daily dosing for systemic effects; however, intranasal administration achieves local therapeutic concentrations with minimal systemic exposure.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Primarily hepatic metabolism (CYP3A4), with metabolites excreted in feces (approximately 87-90%) and urine (<5% unchanged). Less than 5% of a dose is excreted renally as unchanged drug.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid